D. E. Shaw & Co. Inc. Has $4.62 Million Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

D. E. Shaw & Co. Inc. lifted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 38.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,363,452 shares of the company's stock after buying an additional 378,437 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.91% of Xeris Biopharma worth $4,622,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after purchasing an additional 133,738 shares during the period. Geode Capital Management LLC increased its position in Xeris Biopharma by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock worth $11,364,000 after purchasing an additional 17,956 shares during the period. AIGH Capital Management LLC increased its position in Xeris Biopharma by 17.8% in the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock worth $8,729,000 after purchasing an additional 389,192 shares during the period. Renaissance Technologies LLC increased its position in Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after purchasing an additional 500,120 shares during the period. Finally, Northern Trust Corp increased its position in Xeris Biopharma by 3.3% in the fourth quarter. Northern Trust Corp now owns 1,196,381 shares of the company's stock worth $4,056,000 after purchasing an additional 38,155 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Stock Performance

XERS traded down $0.05 during trading hours on Friday, reaching $4.83. The company's stock had a trading volume of 1,451,792 shares, compared to its average volume of 1,961,881. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.86 and a 52 week high of $6.07. The company's 50-day moving average is $4.73 and its 200-day moving average is $3.96. The firm has a market cap of $755.34 million, a PE ratio of -10.73 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This represents a 2.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 6.47% of the company's stock.

Wall Street Analysts Forecast Growth

XERS has been the subject of a number of research reports. Leerink Partners lifted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Finally, Oppenheimer increased their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.